Combined olmesartan, amlodipine, and hydrochlorothiazide therapy in randomized patients with hypertension: a subgroup analysis of the TRINITY study by age.

ABSTRACT:

Background

Hypertension is often inadequately controlled in older people.

Objective

This prespecified subgroup analysis assessed the efficacy and safety of an olmesartan medoxomil (OM) 40 mg/amlodipine besylate (AML) 10 mg/hydrochlorothiazide (HCTZ) 25 mg triple-combination treatment compared with the 3 components as dual-combination treatments in participants with hypertension who were <65 and ≥ 65 years of age. Within the ≥ 65 years of age subgroup, efficacy and safety were also summarized for participants ≥ 75 years of age.

Study design

12-week, multicenter, double-blind, randomized, parallel-group study.

Setting

317 ambulatory care sites in the US and Puerto Rico.

Participants

Individuals ≥ 18 years of age with mean seated blood pressure (SeBP) ≥ 140

SUBMITTER: Lewin AJ 

PROVIDER: S-EPMC3687106 | biostudies-literature | 2013 Jul

REPOSITORIES: biostudies-literature